LABP News and Press, Landos Biopharma Inc. From 06/21/22

Landos Biopharma (NASDAQ:LABP) +5% on Tuesday has announced the appointment of Gregory Oakes as its president and chief effective officer, effective immediately. Oakes most recently served as president, North America, EVP and member of the executive committee of Vifor...

Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:...

Landos Biopharma press release (NASDAQ:LABP): Q1 GAAP EPS of -$0.37. As of March 31, 2022, the Company had cash, cash equivalents and marketable securities of approximately $73.8 million, which it believes will be sufficient to fund planned operations into the second half of 2023. For furth...

On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK, May 12, 2022 (GLOBE ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the start of another day comes our breakdown of the biggest pre-market stock movers and this time it’s for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, heavy volume, and more have sto...

Landos Biopharma press release (NASDAQ:LABP): FY GAAP EPS of -$1.02. FY Cash cash and equivalents $91M For further details see: Landos Biopharma GAAP EPS of -$1.02

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of NX-13 in Ulcerative Colitis and Phase 1a Trial of LABP-104 in Normal ...

BLACKSBURG, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it has appointed Roger Adsett to the Company’s Board of D...

Shares of Landos Biopharma (LABP -20.9%) are down today following downgrades by two Wall Street analysts. SVB Leerink's Thomas Smith downgraded shares to market perform from outperform, and cut his price target to $16 from $20 (14% upside). JonesTrading analyst Prakhar Agrawal cuts shares to ...

Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...